A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Advanced Ovarian Cancer|Triple Negative Breast Cancer
Interventions: DRUG: Atezolizumab|DRUG: RO6870810
Sponsor: Hoffmann-La Roche